New hope for AML patients: Triple-Drug combo targets Tough-to-Treat leukemia

NCT ID NCT07581002

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive either the triple combination or standard care. The goal is to see if the new combo improves remission rates and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pivekimab sunirine, venetoclax, and azacitidine
What this could lead to: If successful, this combination could offer a new, more effective treatment option for AML patients who cannot tolerate intensive chemotherapy.
What could go wrong: This is an early-to-mid-stage trial, so the added benefit over standard care is unproven. Side effects from the combination may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Asan Medical Center /ID# 279395
RECRUITING

Seoul, Seoul Teugbyeolsi, 05505, South Korea
China Medical University Hospital /ID# 279261
RECRUITING

Taichung, 40447, Taiwan
City of Hope National Medical Center /ID# 279568
RECRUITING

Duarte, California, 91010, United States
Hadassah Medical Center-Hebrew University /ID# 278866
RECRUITING

Jerusalem, 91120, Israel
Mayo Clinic Hospital - Phoenix /ID# 282904
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic Hospital Jacksonville /ID# 282903
NOT_YET_RECRUITING

Jacksonville, Florida, 32224, United States
Montefiore Medical Center - Moses Campus /ID# 279399
RECRUITING

The Bronx, New York, 10467, United States
Rambam Health Care Campus- Haifa /ID# 278719
RECRUITING

Haifa, 3109601, Israel
Samsung Medical Center /ID# 279397
RECRUITING

Seoul, Seoul Teugbyeolsi, 06351, South Korea
Shaare Zedek Medical Center /ID# 278712
RECRUITING

Jerusalem, 9103102, Israel
Taichung Veterans General Hospital /ID# 279296
RECRUITING

Taichung, 407, Taiwan
Tel Aviv Sourasky Medical Center /ID# 278717
RECRUITING

Tel Aviv, Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.